Placebo-Controlled Randomized Study of KW-3902 for Subjects Hospitalized With Worsening Renal Function and Heart Failure Requiring IV Therapy

Inclusion Criteria: * Dyspnea at rest or with minimal exertion at randomization * Fluid overload * Estimated creatinine clearance (CrCl) between 20-60 mL/min * Worsening renal function * Anticipated need for IV diuretic treatment for at least 48 hours after the start of study drug * BNP \>500 pg/mL or NT-pro-BNP \>2000 pg/mL * Systolic blood pressure ≥90 mmHg at randomization Exclusion Criteria: * IV radiographic contrast within 14 days * IV vasodilators within 6 hours * Serum potassium \<3.5 meq/L * Ongoing or planned therapy for heart failure with mechanical circulatory or ventilatory support * Ongoing or planned treatment with ultrafiltration, hemofiltration, or dialysis * Rapidly progressive acute renal failure * Evidence of acute tubular necrosis or post-obstructive nephropathy or other exogenous causes of acute kidney injury, unrelated to heart failure * Severe pulmonary disease * Significant stenotic mitral or aortic valvular disease * Heart transplant recipient or admitted for cardiac transplantation or LVAD surgery * Any major surgery within 2 weeks prior * evidence of acute coronary syndrome in the 2 weeks prior * Hgb \<8 g/dL, Hct \<25%, or active bleeding requiring transfusion * Acute myocarditis or hypertrophic obstructive, restrictive, or constrictive cardiomyopathy. * Known hepatic impairment * Non-cardiac pulmonary edema * Temperature \>38°C * Sepsis or active infection requiring IV anti-microbial treatment * Administration of an investigational drug or dev…